ArticleBMC cancer2025
Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasound-guided superficial radiotherapy, a multi-institutional study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recurrence of keratinocyte cancers after superficial radiation therapy.Skin health and disease · 2026Review
- Article
- Geodiamolide A, a Marine Sponge Depsipeptide, Halts Proliferation and Triggers Cell Death in Squamous Cell Carcinoma (A431, NMSC) In Vitro.International journal of molecular sciences · 2026Article
- Radiotherapeutic Modalities and Advancements in the Treatment of Cutaneous Malignancies.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImage-guided superficial radiation therapy (IGSRT) using a high resolution dermal ultrasound, is becoming a non-surgical highly effective treatment option for non-melanoma skin cancer (NMSC). In a previous study, we reported results from a multi-institutional study of 1616 patients with 2917 NMSC lesions treated with IGSRT showing a 99.3% rate of local control (LC) with mean follow-up of 16.06 months.
methodsIn this study, we analyze 133 additional lesions from 93 patients, as well as update previous findings with a longer follow-up duration, and perform subgroup analysis and Kaplan-Meier statistics. A retrospective analysis of 1709 patients with 3,050 Stage 0, I, and II NMSC lesions treated from 2017 to 2020 was performed.
resultsWith image guidance, lesions received a median of 20 fractions of 50, 70, or 100 kilovoltage(kV) IGSRT. Average follow-up was 25.1 months with a maximum follow up of 65.6 months for the entire cohort. Sixty-eight patients expired, with deaths due to unrelated causes, who had no-evidence of disease (NED) at last follow-up prior to death, leading to Disease-Specific-Survival of 100% (Overall survival was 96%). Absolute LC of 99.2% was achieved in 3,027 of 3,050 lesions with overall absolute LC for BCC, SCC, and SCC-is being 99.0%, 99.2%, and 99.8%, respectively. As of January 2022, no other late complications were found. DISCUSSION: These updated results demonstrates that IGSRT should be considered a first-line option for the non-surgical treatment of NMSC as it continues to achieve low complication rates while maintaining a high level of LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.